IDRI has developed the first defined vaccine for leishmaniasis. Following a successful Phase 1 study in the United States, we conducted clinical trials in Peru, Brazil, and Colombia for cutaneous and mucosal leishmaniasis. Further trials are planned in India and Sudan for visceral leishmaniasis and PKDL (post kala-azar dermal leishmaniasis), as well as in South America for forms of cutaneous leishmaniasis. (Read more...)

IDRI has developed the first defined vaccine for tuberculosis in partnership with GlaxoSmithKline. The vaccine showed strong potential in a Phase 1 study; further studies are planned. (Read more...)

IDRI's leprosy eradication program involves strategies for disease detection, treatment, and prevention. With the goal of detecting active and asymptomatic cases of leprosy (also known as Hansen's Disease), our scientists are designing and implementing diagnostic tests. These tests supplement our development of immuno-therapeutic and prophylactic vaccines in order to cure and prevent cases of the disease. (Read more...)

IDRI scientists develop adjuvants and provide expertise in formulating and manufacturing vaccines. (Read more...)

IDRI, together with its collaborators, has developed simple and reliable diagnostic tests for Chagas disease, tuberculosis, and leishmaniasis. The diagnostics use defined antigens and help meet the need for affordable tests, which facilitate control of disease. 

IDRI seeks to facilitate the self-sustaining production of vaccines, therapeutics, and diagnostics by transfer of manufacturing to capable sites in the countries that need them. For the purpose of enabling production, IDRI seeks intellectual property rights early in development to protect the ability of these sites to manufacture products without threat of litigation.